Derik De Bruin
Stock Analyst at B of A Securities
(4.95)
# 12
Out of 4,810 analysts
210
Total ratings
63.64%
Success rate
82.61%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $8.01 | +37.33% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $43.67 | +48.84% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $9.50 | +68.42% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $323.44 | +26.76% | 13 | Feb 13, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $156 | $103.12 | +51.28% | 32 | Jan 27, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $95.54 | +44.44% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $441.00 | +49.66% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $149.15 | +57.56% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $105.85 | +98.39% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $212.50 | +67.06% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $22.64 | +14.84% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $226.02 | +19.90% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $167.23 | +8.83% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $38.43 | +108.17% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $189.92 | +52.70% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $16.81 | -10.77% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $4.86 | +332.10% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $8.16 | +206.37% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $25.60 | +25.02% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $74.59 | +34.07% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $57.86 | +48.63% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.37 | +285.76% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,046.58 | +45.71% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.10 | +209.52% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $145.29 | +78.96% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.25 | +1,354.55% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $41.53 | +50.71% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $149.22 | -19.58% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.01 | +347.76% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $404.02 | -41.83% | 3 | Nov 2, 2018 |
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $8.01
Upside: +37.33%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $43.67
Upside: +48.84%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.50
Upside: +68.42%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $323.44
Upside: +26.76%
Agilent Technologies
Jan 27, 2025
Maintains: Neutral
Price Target: $150 → $156
Current: $103.12
Upside: +51.28%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $95.54
Upside: +44.44%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $441.00
Upside: +49.66%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $149.15
Upside: +57.56%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $105.85
Upside: +98.39%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $212.50
Upside: +67.06%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.64
Upside: +14.84%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $226.02
Upside: +19.90%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $167.23
Upside: +8.83%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $38.43
Upside: +108.17%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $189.92
Upside: +52.70%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $16.81
Upside: -10.77%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $4.86
Upside: +332.10%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $8.16
Upside: +206.37%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $25.60
Upside: +25.02%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $74.59
Upside: +34.07%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $57.86
Upside: +48.63%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.37
Upside: +285.76%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,046.58
Upside: +45.71%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.10
Upside: +209.52%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $145.29
Upside: +78.96%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.25
Upside: +1,354.55%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $41.53
Upside: +50.71%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $149.22
Upside: -19.58%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.01
Upside: +347.76%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $404.02
Upside: -41.83%